BR0213291A - Composição e método para tratamento de diabetes - Google Patents

Composição e método para tratamento de diabetes

Info

Publication number
BR0213291A
BR0213291A BR0213291-5A BR0213291A BR0213291A BR 0213291 A BR0213291 A BR 0213291A BR 0213291 A BR0213291 A BR 0213291A BR 0213291 A BR0213291 A BR 0213291A
Authority
BR
Brazil
Prior art keywords
composition
treating diabetes
ingap
formulation
islet neogenesis
Prior art date
Application number
BR0213291-5A
Other languages
English (en)
Inventor
Aaron I Vinik
Lawrence Rosenberg
Gary Pittenger
David Taylor-Fishwick
Michael Salem
Scott Mohrland
Original Assignee
Gmp Endotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gmp Endotherapeutics Inc filed Critical Gmp Endotherapeutics Inc
Publication of BR0213291A publication Critical patent/BR0213291A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/474—Pancreatic thread protein; Reg protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4733—Acute pancreatitis-associated protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"COMPOSIçãO E MéTODO PARA TRATAMENTO DE DIABETES". A presente invenção refere-se a regimes de dosagem e formulações de proteínas associadas à neogênese de ilhotas (INGAP ou "Islet NeoGenesis Associated Protein") e Peptídeo INGAP. A formulação aqui apresentada demonstrou ter estabilidade aceitável para uma composição farmacêutica. Além disso, a formulação é capaz de regenerar ilhotas funcionais.
BR0213291-5A 2001-10-16 2002-10-15 Composição e método para tratamento de diabetes BR0213291A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32933001P 2001-10-16 2001-10-16
PCT/US2002/032904 WO2003033808A2 (en) 2001-10-16 2002-10-15 Composition and method for treating diabetes

Publications (1)

Publication Number Publication Date
BR0213291A true BR0213291A (pt) 2004-10-26

Family

ID=23284879

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213291-5A BR0213291A (pt) 2001-10-16 2002-10-15 Composição e método para tratamento de diabetes

Country Status (20)

Country Link
US (2) US20040132644A1 (pt)
EP (1) EP1435995A2 (pt)
JP (1) JP2005506362A (pt)
KR (1) KR20050036865A (pt)
CN (1) CN1723034A (pt)
BR (1) BR0213291A (pt)
CA (1) CA2463769A1 (pt)
CO (2) CO5570658A2 (pt)
CZ (1) CZ2004479A3 (pt)
HU (1) HUP0401612A3 (pt)
IL (1) IL161073A0 (pt)
MA (1) MA27503A1 (pt)
MX (1) MXPA04003526A (pt)
NO (1) NO20042012L (pt)
PE (1) PE20030608A1 (pt)
PL (1) PL370069A1 (pt)
RU (1) RU2004114865A (pt)
SK (1) SK1702004A3 (pt)
WO (1) WO2003033808A2 (pt)
ZA (1) ZA200402261B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037277A2 (en) * 2002-10-24 2004-05-06 Mcgill University Use of ingap for reversing diabetes
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
US8211430B2 (en) * 2005-03-04 2012-07-03 Curedm Group Holdings, Llc Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
US7393919B2 (en) 2005-05-25 2008-07-01 Cure Dm, Inc. Peptides, derivatives and analogs thereof, and methods of using same
EP1840573A1 (en) * 2006-03-27 2007-10-03 Institut Pasteur Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections
US8785400B2 (en) * 2006-11-22 2014-07-22 Curedm Group Holdings, Llc Methods and compositions relating to islet cell neogenesis
KR20100080519A (ko) * 2007-08-30 2010-07-08 큐어디엠 인코포레이티드 프로섬 펩타이드 및 이의 유사체의 조성물 및 이의 이용 방법
JP2015533821A (ja) * 2012-09-27 2015-11-26 クラレッサ レヴェタンＣｌａｒｅｓａ ＬＥＶＥＴＡＮ 新たな膵臓ベータ細胞の生成
CN104045698B (zh) * 2013-03-15 2019-04-16 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物
CN104045699A (zh) * 2013-03-15 2014-09-17 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物
WO2014139182A1 (en) * 2013-03-15 2014-09-18 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
CN104045702A (zh) * 2013-03-15 2014-09-17 深圳君圣泰生物技术有限公司 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物
CN103305457B (zh) * 2013-06-06 2015-07-08 浙江省医学科学院 一种体外扩增胰岛β细胞的方法
US9321812B2 (en) * 2014-03-28 2016-04-26 Perle Bioscience Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide
WO2017152861A1 (en) * 2016-03-10 2017-09-14 Shenzhen Hightide Biopharmaceutical, Ltd. Conjugates of islet neogenesis peptides and analogs, and methods thereof
WO2020036918A1 (en) * 2018-08-15 2020-02-20 Wake Forest University Health Sciences Improved formulations for pancreatic islet encapsulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US127624A (en) * 1872-06-04 Improvement in apparatus for elevating water
US4658957A (en) * 1985-01-28 1987-04-21 Abbott Laboratories Utility tray
US6106840A (en) * 1988-06-23 2000-08-22 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
DE69638315D1 (de) * 1995-02-22 2011-02-17 Eastern Virginia Med School Ingap-protein und dessen beteiligung an der neogenese pankreatischer inselzellen
US5834590A (en) * 1995-02-22 1998-11-10 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Ingap protein involved in pancreatic islet neogenesis
JP4426650B2 (ja) * 1996-05-03 2010-03-03 アボット・ラボラトリーズ 新規な抗血管形成ペプチド、それをコードするポリヌクレオチド、および血管形成を阻害する方法
US6090577A (en) * 1997-05-22 2000-07-18 Incyte Pharmaceuticals, Inc. Disease associated acidic protein
US6986994B2 (en) * 2001-01-09 2006-01-17 Gmp Endotherapeutics, Inc. INGAP displacement assays

Also Published As

Publication number Publication date
CO5570658A2 (es) 2005-10-31
EP1435995A2 (en) 2004-07-14
SK1702004A3 (sk) 2005-03-04
ZA200402261B (en) 2004-09-28
HUP0401612A2 (hu) 2004-12-28
JP2005506362A (ja) 2005-03-03
KR20050036865A (ko) 2005-04-20
MXPA04003526A (es) 2004-07-22
CO5590933A2 (es) 2005-12-30
US20080171704A1 (en) 2008-07-17
HUP0401612A3 (en) 2006-04-28
IL161073A0 (en) 2004-08-31
PL370069A1 (en) 2005-05-16
WO2003033808A2 (en) 2003-04-24
MA27503A1 (fr) 2005-09-01
RU2004114865A (ru) 2005-05-27
PE20030608A1 (es) 2003-08-26
CN1723034A (zh) 2006-01-18
CZ2004479A3 (cs) 2005-01-12
CA2463769A1 (en) 2003-04-24
NO20042012L (no) 2004-07-16
WO2003033808A3 (en) 2003-09-18
US20040132644A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
BR0213291A (pt) Composição e método para tratamento de diabetes
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
DE69531741D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
DE69831971D1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
HUP0000492A1 (hu) N-(Aril/heteroaril-acetil)-aminosav-észterek, azokat tartalmazó gyógyászati készítmények, valamint módszerek béta-amiloid fehérje képződése és felszabadulása gátlására e vegyületek felhasználásával
HUP0300684A2 (hu) Szomatosztatin analógok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE380037T1 (de) Verfaheren zur durch rekombinante adeno- assoziierte virus-gerichtete gentherapie
ATE466085T1 (de) Protease-resistente modifizierte interferon alpha polypeptide
MX9703643A (es) Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana.
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
ATE75945T1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
BR9714358A (pt) Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
HUP0301349A2 (hu) IL-11-tartalmú készítmények
MX9703642A (es) Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana.
ATE83663T1 (de) Imipramin enthaltende arzneizubereitungen.
DK1079849T3 (da) Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning
DE69409237D1 (de) Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten
CL2004001484A1 (es) Compuestos derivados de 2,4,5-triaril imidazolinas, inhibidores de la interaccion de la proteina mdm2 con un peptido del tipo p53; composicion farmaceutica; y su uso para preparar un medicamento para tratar trastornos de proliferacion celular, tales
ATE546461T1 (de) Gnrh analog von nicht-säugertieren und verwendung zur regulierung der fruchtbarkeit und der schwangerschaft
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
BR0309966A (pt) Muteìnas de fator de crescimento placentário tipo 1, método de preparação e seus usos
BR0109279A (pt) Antagonistas de lhrh, sua preparação e aplicação como medicamento
ATE371737T1 (de) Proteaseresistente flint-analoge
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 4A., 5A., 6A. E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2034 DE 29/12/2009.